ADV ACT logo color.jpg
Occlusion Perfusion Catheter Demonstrates Superior Performance in PAD Drug Delivery
02 nov. 2023 08h28 HE | Advanced Catheter Therapies
Researchers successfully demonstrate the delivery of liquid sirolimus into the arterial wall using the OPC, which can also be used for paclitaxel BTK.
AI Therapeutics Logo.jpg
AI Therapeutics Announces Initiation of a Phase 2 Clinical Trial of LAM-001 for Treatment of Pulmonary Arterial Hypertension (PAH)
31 août 2023 10h38 HE | AI Therapeutics, Inc.
GUILFORD, Conn., Aug. 31, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation...
GMILogo_Vertical-Gradient.png
Drug-eluting Balloon Catheters Market to hit USD 1 billion by 2030, says Global Market Insights Inc.
07 nov. 2022 08h10 HE | Global Market Insights Inc.
Selbyville, Delaware, Nov. 07, 2022 (GLOBE NEWSWIRE) -- The global drug-eluting balloon catheters market value is poised to surpass USD 1 billion by 2030, according to a new research report by...
GMILogo_Vertical-Gradient.png
Drug-Eluting Balloon Catheters Market to hit USD 916 Million by 2028, Says Global Market Insights Inc.
13 avr. 2022 07h15 HE | Global Market Insights Inc.
Selbyville, Delaware, April 13, 2022 (GLOBE NEWSWIRE) -- Global drug-eluting balloon catheters market value is anticipated to reach USD 916 million by 2028, according to a new research report by...
fior-markets-logo.jpg
Global Drug-Eluting Bioabsorbable Stents Market Is Expected to Reach USD 579.87 Million by 2027 : Fior Markets
29 sept. 2020 19h00 HE | Fior Markets
Newark, NJ, Sept. 29, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global drug-eluting bioabsorbable stents market is expected to grow from USD 393.31 million in 2019...
Palvella Logo.png
Palvella Therapeutics Appoints Rare Disease Senior Executive Elaine J. Heron, PhD to Board of Directors
05 sept. 2018 08h00 HE | Palvella Therapeutics
Wayne, PA, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...